Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis

Table 3 The results of safety outcome findings in the meta-analysis

Outcome variables	No. of RCT included	No. of participants with outcome/participants analyzed		Pooled effect size, RR (95%CI)	I2 (%)	P value
		Beinaglutide arm	Control arm
At least one AE	2	252/311	113/166	2.90 (0.28 to 30.29)	83	0.37
Serious AEs	2	8/350	1/205	1.80 (0.08 to 42.54)	55	0.71
Treatment discontinuation for any reason	5	36/198	29/196	1.22 (0.79 to 1.90)	0	0.37
Treatment discontinuation due to AEs	5	31/452	6/305	3.15 (1.32 to 7.54)	0	0.010
Nausea	5	191/417	27/270	4.51 (1.16 to 17.53)	87	0.03
Vomiting	4	77/382	2/237	8.19 (2.32 to 28.90)	15	0.001
Diarrhea	4	17/382	37 /237	0.27 (0.04 to 1.67)	63	0.16
Palpitation	2	18/325	2/180	3.95 (1.06 to 14.80)	0	0.04
Fatigue	3	19/357	4/212	2.53 (0.91 to 7.04)	0	0.08
Headache	4	36/382	6/237	2.87 (1.31 to 6.32)	0	0.009
Dizziness	3	76/350	7/205	6.07 (2.92 to 12.61)	0	< 0.00001
Upper RTI	3	28/350	14/205	0.99 (0.54 to 1.81)	0	0.98
Hypoglycemia	3	6/99	9/97	0.64 (0.2 to 1.92)	7	0.43

AE: Adverse event; RCT: Randomized controlled trial; 95%CI: 95% confidence interval; RR: Risk ratio; RTI: Respiratory tract infection.